Clincosm LogoSign in Get a demo

egfr activating mutation

Showing 1 - 24 of 24
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19 Trial in France (Plasma ctDNA, FFPE blocks)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +3 more
  • Plasma ctDNA
  • FFPE blocks
  • Angers, France
  • +35 more
Sep 19, 2023

NSCLC, EGFR Activating Mutation, Brain Metastases Trial in Beijing (TY-9591, Osimertinib)

Not yet recruiting
  • NSCLC
  • +2 more
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospitial,Chinese Academy of Medic
Jul 9, 2023

Aumolertinib, Anlotinib, TP53 Trial (Aumolertinib,Anlotinib)

Not yet recruiting
  • Aumolertinib
  • +4 more
  • (no location specified)
Mar 8, 2023

Brain Metastases, Radiotherapy, EGFR Activating Mutation Trial in Guangdong (brain radiotherapy, Almonertinib)

Recruiting
  • Brain Metastases
  • +2 more
  • Guangdong, Guangzhou, China
    Sun-Yat-Sen university
Mar 13, 2023

NSCLC, EGFR Activating Mutation Trial in Changsha, Shanghai (TY-9591, Osimertinib, Osimertinib)

Recruiting
  • NSCLC
  • EGFR Activating Mutation
  • Changsha, Hunan, China
  • +1 more
Dec 6, 2022

Lung Tumors, NSCLC, Respiratory Tract Tumors Trial in Worldwide (BLU-945, osimertinib)

Recruiting
  • Lung Neoplasms
  • +23 more
  • La Jolla, California
  • +35 more
Oct 6, 2022

NSCLC, EGFR Activating Mutation Trial in Guangzhou (Sintilimab, Carboplatin, Nab paclitaxel)

Recruiting
  • Non-small Cell Lung Cancer
  • EGFR Activating Mutation
  • Sintilimab
  • +2 more
  • Guangzhou, Guangdong, China
    Guangdong Lung Cancer Institute, Guangdong Provincial People's H
Aug 8, 2022

Non-squamous Non-small-cell Lung Cancer, EGFR Activating Mutation Trial in Japan (Pembrolizumab, Lenvatinib, Carboplatin)

Recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • EGFR Activating Mutation
  • Urayasu, Chiba, Japan
  • +9 more
Jul 19, 2022

Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases Trial in France (Osimertinib)

Recruiting
  • Non Small Cell Lung Cancer Metastatic
  • +3 more
  • Aix-en-Provence, France
  • +36 more
Jun 28, 2022

Lung Tumor, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-701, osimertinib, carboplatin)

Recruiting
  • Lung Neoplasm
  • +26 more
  • Boston, Massachusetts
  • +6 more
Jun 23, 2022

NSCLC, EGFR Activating Mutation, Brain Metastases Trial in Beijing (TY-9591 Tablets)

Recruiting
  • NSCLC
  • +3 more
  • TY-9591 Tablets
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospitial,Chinese Academy of Medic
May 14, 2022

Lung Tumor Malignant, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-451)

Recruiting
  • Lung Neoplasm Malignant
  • +18 more
  • Fairfax, Virginia
    New Experimental Therapeutics of Virginia (NEXT Oncology)
Mar 29, 2022

Nsclc, EGFR Activating Mutation, EGF-R Positive NSCLC Trial in Hong Kong (Pembrolizumab, Lenvatinib, Pemetrexed)

Recruiting
  • Nsclc
  • +5 more
  • Hong Kong, Hong Kong
    Queen Mary Hospital
Nov 25, 2021

Lung Cancer, Lung Adenocarcinoma, EGFR Activating Mutation Trial in Vandoeuvre-lès-Nancy (Collection of surgical waste)

Enrolling by invitation
  • Lung Cancer
  • +4 more
  • Collection of surgical waste
  • Vandoeuvre-lès-Nancy, Lorraine, France
    Seitlinger
Nov 24, 2021

NSCLC, Leptomeningeal Metastasis, EGFR Activating Mutation Trial in Nanchang (Almonertinib, Bevacizumab)

Not yet recruiting
  • NSCLC
  • +2 more
  • Nanchang, Jiangxi, China
    The Second Afiliated Hospital of Nanchang University
Jun 26, 2021

Followed by 3rd Generation EGFR-TKI in EGFR Mutation Positive

Recruiting
  • EGFR Activating Mutation
  • +3 more
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Feb 23, 2021

EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma, Stage IV NSCLC Trial in Winston-Salem (drug, biological,

Terminated
  • EGFR Activating Mutation
  • +2 more
  • Winston-Salem, North Carolina
    Comprehensive Cancer Center of Wake Forest University
Jan 28, 2021

Non Small Cell Lung Cancer, Stage III NSCLC, EGFR Activating Mutation Trial in Hangzhou (Almonertinib)

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Hangzhou, Zhejiang, China
    Hangzhou Cancer hospital
Jan 8, 2021

Non Small Cell Lung Cancer, Surgery, EGFR Activating Mutation Trial (Neoadjuvant treatment: Afatinib, pemetrexed, gemcitabine,

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +4 more
  • Neoadjuvant treatment: Afatinib, pemetrexed, gemcitabine, cisplatin, carboplatin
  • +2 more
  • (no location specified)
Jul 12, 2020

Leptomeningeal Metastasis, NSCLC, EGFR Activating Mutation Trial (Osimertinib, Bevacizumab)

Unknown status
  • Leptomeningeal Metastasis
  • +2 more
  • (no location specified)
Nov 1, 2019

Lung Adenocarcinoma, EGFR Activating Mutation Trial (icotinib combined with pemetrexed plus cisplatin, first icotinib and then

Completed
  • Lung Adenocarcinoma
  • EGFR Activating Mutation
  • icotinib combined with pemetrexed plus cisplatin
  • first icotinib and then pemetrexed plus cisplatin
  • (no location specified)
Oct 11, 2019

NSCLC Stage IIIB, NSCLC Stage IV, EGFR Activating Mutation Trial in Hong Kong (Atezolizumab, Bevacizumab, Carboplatin)

Unknown status
  • NSCLC Stage IIIB
  • +2 more
  • Hong Kong, Hong Kong
    Department of Clinical Oncology
Apr 16, 2019

ALK Gene Translocation, EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma Trial in Seattle (Nivolumab,

Terminated
Has Results
  • ALK Gene Translocation
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Feb 27, 2019

NSCLC Metastatic, EGFR Activating Mutation Trial in Chengdu (Gefitinib, gemcitabine, carboplatin)

Terminated
  • Non-small Cell Lung Cancer Metastatic
  • EGFR Activating Mutation
  • Chengdu, Sichuan, China
    China West Hospital
Nov 23, 2017